Literature DB >> 22735753

Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes.

James M Foran1, Jamile M Shammo.   

Abstract

Myelodysplastic syndromes (MDS) comprise a group of underrecognized hematologic clonal malignancies with variable propensity for leukemic transformation that can present a diagnostic challenge because they lack hallmark symptoms. MDS can present with varying degrees of anemia, neutropenia, and thrombocytopenia, and at presentation can range from indolent to life threatening. The clinician should have a heightened level of suspicion when treating elderly patients and those with prior exposure to chemotherapy, radiation, and environmental toxins in the presence of unexplained cytopenias. Chronic anemia should not be considered a natural consequence of aging. Approximately 1 in 6 patients with unexplained anemia may have findings compatible with MDS, suggesting that MDS should be considered higher in the differential diagnosis. Primary care physicians are encouraged to conduct comprehensive evaluations to exclude non-MDS-related causes for persistent cytopenias. Patients with pancytopenia, bicytopenia, or any persistent and unexplained isolated cytopenia (and particularly unexplained macrocytic anemia) should be referred to a specialist to establish a diagnosis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22735753     DOI: 10.1016/j.amjmed.2012.04.015

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  19 in total

1.  Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.

Authors:  Julie Waisbren; Shira Dinner; Jessica Altman; Olga Frankfurt; Irena Helenowski; Juehua Gao; Brandon J McMahon; Brady L Stein
Journal:  Int J Hematol       Date:  2016-08-24       Impact factor: 2.490

2.  Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia.

Authors:  Amelia Huck; Olga Pozdnyakova; Andrew Brunner; John M Higgins; Amir T Fathi; Robert P Hasserjian
Journal:  Leuk Res       Date:  2015-06-28       Impact factor: 3.156

3.  Lentiviral vector-mediate ATG3 overexpression inhibits growth and promotes apoptosis of human SKM-1 cells.

Authors:  Lin Wang; Jin Song; Jing Zhang; Chen Zhu; Yan Ma; Xiaoping Xu
Journal:  Mol Biol Rep       Date:  2014-01-14       Impact factor: 2.316

Review 4.  Myelodysplastic syndromes: what do hospitalists need to know?

Authors:  Amer M Zeidan; Bishoy Faltas; B Douglas Smith; Steven Gore
Journal:  J Hosp Med       Date:  2013-05-11       Impact factor: 2.960

Review 5.  The myelodysplastic syndrome as a prototypical epigenetic disease.

Authors:  Jean-Pierre J Issa
Journal:  Blood       Date:  2013-05-09       Impact factor: 22.113

6.  NeuCode Proteomics Reveals Bap1 Regulation of Metabolism.

Authors:  Joshua M Baughman; Christopher M Rose; Ganesh Kolumam; Joshua D Webster; Emily M Wilkerson; Anna E Merrill; Timothy W Rhoads; Rajkumar Noubade; Paula Katavolos; Justin Lesch; Donald S Stapleton; Mary E Rabaglia; Kathy L Schueler; Raymond Asuncion; Melanie Domeyer; Jose Zavala-Solorio; Michael Reich; Jason DeVoss; Mark P Keller; Alan D Attie; Alexander S Hebert; Michael S Westphall; Joshua J Coon; Donald S Kirkpatrick; Anwesha Dey
Journal:  Cell Rep       Date:  2016-06-30       Impact factor: 9.423

7.  Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients.

Authors:  Emily S Reese; Eberechukwu Onukwugha; Nader Hanna; Brian S Seal; C Daniel Mullins
Journal:  Cancer Med       Date:  2013-10-10       Impact factor: 4.452

Review 8.  Rethinking clinical trial endpoints in myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; David P Steensma
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

9.  Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm.

Authors:  Yasmin Mair; Yan Zheng; Donghong Cai
Journal:  N Am J Med Sci       Date:  2013-05

10.  Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies.

Authors:  Yan-Fung Wong; Lars Martin Jakt; Shin-Ichi Nishikawa
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.